Pawlotsky jm résist tt hcv 2014
HIV/HCV Coinfection News – HCV Protease Inhibitors Juergen Rockstroh, MD Marc Poliquin, MD.
SILEN-C2: sustained virological response (SVR) and safety of BI 201335 combined with peginterferon alfa 2a and ribavirin (PegIFN/RBV) in chronic HCV genotype-1.
José M. Miró, 1 Miguel Montejo, 2 Lluis Castells, 3 Antonio Rimola, 1 Antonio Rafecas, 4 Pilar Miralles, 5 Jesús Fortún, 6 Marino Blanes, 7 Manuel de la.
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.
Pawlotsky du 2012 hepatites-resistance
Benhamou co infection
Pawlotsky resistance
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.
Francesco NEGRO. Steatosis and Chronic Hepatitis C: liaisons dangéreuses? Francesco Negro Unité de Viropathologie Centre Médical Universitaire Genève.
Hepatitis C virus A new era Kate Nash Consultant Hepatologist Southampton.
Hepatitis C: Hidden Harm Friday 21 st March, 2014 Dublin Hepatitis C – A Public Health Issue Joe Barry, TCD.